NCT05512546

Brief Summary

Clopidogrel has been to be reported to be superior to aspirin for the prevention of thromboembolic complications associated with coil embolization in patients with ruptured aneurysms.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2017

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 10, 2017

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 10, 2020

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 10, 2020

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

August 21, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 23, 2022

Completed
Last Updated

August 23, 2022

Status Verified

August 1, 2022

Enrollment Period

3 years

First QC Date

August 21, 2022

Last Update Submit

August 21, 2022

Conditions

Thromboembolic StrokeAspirinClopidogrelCoil EmbolizationPrevention

Outcome Measures

Primary Outcomes (2)

  • High Intensity Areas

    post procedural

    at 24 hours

  • High Intensity Areas

    Post Procedural

    3 months

Secondary Outcomes (1)

  • High Intensity Areas

    at 6 months

Study Arms (2)

Aspirin Group

patients were prescribed 75 mg/day of either aspirin for 6 months

Drug: Aspir-Low Pill

Clopidogrel Group

75mg/day prescribed for 6 months

Drug: Aspir-Low Pill

Interventions

Aspir-Low PillDRUG

patients were prescribed 75 mg/day of either aspirin

Aspirin GroupClopidogrel Group

Eligibility Criteria

Age45 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients with ruptured cerebral hemorrhage

You may qualify if:

  • All the patients enrolled in the study underwent MRI and Angiography.
  • Participants included in the study were confirmed on assessment, and verified for ruptured aneurysm by imaging using either computed tomography (CT) or MRI.

You may not qualify if:

  • Patients with any history of sensitivity or reaction to aspirin, or any contraindication for MRI, were excluded from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Umair Rasheed

Lahore, Punjab Province, 54000, Pakistan

Location

MeSH Terms

Interventions

Aspirin

Intervention Hierarchy (Ancestors)

SalicylatesHydroxybenzoatesPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Study Officials

  • Umair Rasheed, FRCPS

    Lahore General Hospital

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Registrar Neurology

Study Record Dates

First Submitted

August 21, 2022

First Posted

August 23, 2022

Study Start

February 10, 2017

Primary Completion

February 10, 2020

Study Completion

December 10, 2020

Last Updated

August 23, 2022

Record last verified: 2022-08

Locations

PA(1)